This is a call to the world’s visionaries who made waves. The ones who gave themselves the green light to turn bold dreams into disruptive realities and shake up the status quo. Hear straight from industry leaders across tech, healthcare, and life sciences as they share their stories and innovations with us. This is from Dreamers to Disruptors, a Medidata podcast.

Available on:

As life expectancy increases and survival rates for cancer and heart disease improve, central nervous system (CNS) conditions are increasingly becoming a focus in healthcare. The search to treat Alzheimer’s disease and other forms of dementia grows every day as more people feel their impact.

Cogstate CEO Brad O’Connor has over 20 years of experience driving his company to expand our collective knowledge and ability to detect CNS diseases as we work towards a cure for dementia. He and Medidata CEO Anthony Costello explore this critical and challenging area of clinical research, plus the strides being made to advance it.

Brad shares Cogstate’s work to develop new treatments and reliable, universal tests for assessing changes in cognition. From blood-based biomarkers to AI-powered clinical trials, Brad and Anthony outline a future for people with Alzheimer’s where earlier identification of risk factors leads to longer, happier lives for patients and loved ones.